Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Receives $195.08 Average Price Target from Brokerages

Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) have been given an average recommendation of “Moderate Buy” by the thirteen research firms that are presently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and eleven have issued a buy recommendation on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $195.08.

A number of analysts have commented on JAZZ shares. HC Wainwright decreased their price target on shares of Jazz Pharmaceuticals from $204.00 to $200.00 and set a “buy” rating for the company in a research note on Thursday, March 14th. Stifel Nicolaus boosted their price objective on Jazz Pharmaceuticals from $225.00 to $230.00 and gave the stock a “buy” rating in a report on Friday, March 15th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $195.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, February 29th. UBS Group cut their price target on shares of Jazz Pharmaceuticals from $135.00 to $131.00 and set a “neutral” rating for the company in a research note on Friday, March 1st. Finally, Robert W. Baird started coverage on shares of Jazz Pharmaceuticals in a research report on Wednesday, January 3rd. They set an “outperform” rating and a $160.00 price objective on the stock.

Insiders Place Their Bets

In other news, CFO Philip L. Johnson bought 12,000 shares of the business’s stock in a transaction dated Friday, March 1st. The shares were purchased at an average price of $119.65 per share, for a total transaction of $1,435,800.00. Following the completion of the acquisition, the chief financial officer now owns 27,932 shares of the company’s stock, valued at $3,342,063.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, CFO Philip L. Johnson bought 12,000 shares of the company’s stock in a transaction dated Friday, March 1st. The stock was bought at an average cost of $119.65 per share, for a total transaction of $1,435,800.00. Following the completion of the acquisition, the chief financial officer now owns 27,932 shares in the company, valued at approximately $3,342,063.80. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO Patricia Carr sold 1,936 shares of the firm’s stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $119.64, for a total value of $231,623.04. Following the completion of the sale, the chief accounting officer now directly owns 8,364 shares in the company, valued at $1,000,668.96. The disclosure for this sale can be found here. Insiders own 4.40% of the company’s stock.

Institutional Trading of Jazz Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its holdings in Jazz Pharmaceuticals by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 6,379,053 shares of the specialty pharmaceutical company’s stock worth $825,705,000 after purchasing an additional 29,960 shares in the last quarter. Wellington Management Group LLP raised its stake in Jazz Pharmaceuticals by 7.5% in the first quarter. Wellington Management Group LLP now owns 2,625,134 shares of the specialty pharmaceutical company’s stock worth $408,654,000 after buying an additional 184,124 shares in the last quarter. State Street Corp lifted its holdings in Jazz Pharmaceuticals by 1.8% in the second quarter. State Street Corp now owns 2,372,395 shares of the specialty pharmaceutical company’s stock worth $294,106,000 after buying an additional 42,703 shares during the period. LSV Asset Management boosted its position in Jazz Pharmaceuticals by 2.4% during the 3rd quarter. LSV Asset Management now owns 2,372,177 shares of the specialty pharmaceutical company’s stock valued at $307,055,000 after acquiring an additional 55,630 shares in the last quarter. Finally, FMR LLC boosted its position in Jazz Pharmaceuticals by 8.1% during the 3rd quarter. FMR LLC now owns 1,333,129 shares of the specialty pharmaceutical company’s stock valued at $172,560,000 after acquiring an additional 100,349 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Price Performance

JAZZ stock opened at $116.42 on Wednesday. The company has a debt-to-equity ratio of 1.37, a current ratio of 2.24 and a quick ratio of 1.85. The company’s 50-day moving average is $122.31 and its 200-day moving average is $123.75. The stock has a market capitalization of $7.33 billion, a PE ratio of 19.02, a price-to-earnings-growth ratio of 1.61 and a beta of 0.59. Jazz Pharmaceuticals has a 1 year low of $111.25 and a 1 year high of $147.98.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 earnings per share for the quarter, missing analysts’ consensus estimates of $4.44 by ($0.04). Jazz Pharmaceuticals had a return on equity of 31.27% and a net margin of 10.82%. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1.01 billion. Equities research analysts expect that Jazz Pharmaceuticals will post 16.24 EPS for the current fiscal year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.